Placeholder Banner

RegeneRx’s TB4 shows functional recovery in MS animal model

September 30, 2009
RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) announces significant improvement in neurological functional recovery after TB4 treatment of EAE (experimental autoimmune encephalomyelitis - an animal model for multiple sclerosis), according to Henry Ford Health System researchers. In addition, researchers reported a significant reduction of inflammation and induction of oligodendrogenesis (maturation of central nervous system cells associated with the formation of the nerve sheath). The study entitled, "Neurological Functional Recovery after Thymosin Beta 4 Treatment in Mice with Experimental Auto Encephalomyelitis," was published online ahead of print in Neuroscience, 2009 September 24. The publication highlights the statistically significant effects of TB4 treatment in EAE mice, including improvement of neurological functional recovery, reduction of inflammatory infiltrates in the brain, and increase of oligodendrocyte progenitor cells (a type of stem cell) and mature oligodendrocytes in the brain.
Read the release.